AQW 40761/22-27


Mrs Diane Dodds
Democratic Unionist Party
Upper Bann


Tabled Date: 17/02/2026
Answered On Date: 03/08/2026
Priority Written: No


Question:
To ask the Minister of Health for his assessment of the Cass Assessment Report for Gender Identity Services.


Answer:
I welcomed the report from Baroness Hilary Cass of her assessment of Gender Identity Services in Northern Ireland, published by my department on 10 February 2026 noting that it found that Northern Ireland’s gender identity services align with the 2024 Cass Review and place the region in a strong position to develop a safe, evidencebased Lifespan Gender Identity Service. The Cass Assessment Report positively reflects the integration of Northern Ireland Child and Adolescent Mental Health Service, and clinical and social services.  My officials are currently considering the contents of the report and its implications for service delivery in Northern Ireland including the reference to the forthcoming National Health Service England (NHSE) service specification for use in England from April 2026 to ensure consistency with NHS England services as far as possible.
There are six key recommendations outlined in the Cass Assessment Report, recommendations 1-3 relate to workforce, integration with paediatric services and clinical leadership within the under-18’s service and are suggestions to make the NI service consistent with the services in England, regardless of whether or not Northern Ireland joins the UK National Provider Network and research programme.
Recommendations 4-6 are required to enable NI to join the UK National Provider Network and participate in the research programme but as you will be aware, I decided to suspend Northern Ireland’s participation in the clinical trial given there is a Judicial Review underway in England.
My officials are currently considering the recommendations in the report, and they are working alongside Health and Social Care service providers in Northern Ireland to understand the implications of their implementation in advance of linking in with their counterparts in England to progress them.
However, in the meantime the recruitment and training of new staff will be the immediate priority, funding of £806k for the new Regional Lifespan Gender Identity Service was allocated to the Belfast Health and Social Care Trust, enabling recruitment to begin from December 2025, with the projected start date for service delivery to be confirmed as recruitment progresses.   It will take some time for the new model of care to fully embed therefore the immediate focus will be on hiring and training staff. The new structure includes expanded psychology, governance and endocrine teams, addressing the main weaknesses in the current pathway, and is designed to support care aligned with international best practice. 
 
There is a level of compliance within the Cass Report recommendations that the Regional Lifespan Gender Identity Service aims to put in place, including aligning clinical practice so that standards of care in Northern Ireland are consistent with those in England. This will allow shared clinical improvement initiatives, shared learning and a peer network to support consistency of the care model.
However, a small number of clinical recommendations will need to be considered by the Belfast Trust’s clinical and management teams to determine if they are feasible within available resources and change management capacity.
Overall, Baroness Cass and her team have determined that the approved funding presents a crucial opportunity to reopen the endocrine service at the same time as developing a new lifespan model of care and building the foundations for a collaborative relationship with the under-18’s English services. Baroness Cass commented that the current model between the Child and Adolescent Mental Health Service and the Knowing our Identity service is a key asset of the NI approach, as is the chance to have a seamless interface across the age range.
In respect of the puberty blockers trial, in December 2024, following publication of the Cass Review, I sought and secured Executive agreement in December 2024 to introduce an indefinite ban on private prescribing of puberty blockers for under 18s in Northern Ireland, due to safety concerns. As referenced earlier, the recent Cass Assessment Report reiterated the need for a more robust safety framework regarding prescribing puberty blockers and made recommendations to bring Northern Ireland into line with England’s service standards that would enable people from Northern Ireland to take part in the PATHWAYS trial.
However, on 14 February 2026, I suspended Northern Ireland’s participation in PATHWAYS pending the outcome of a Judicial Review in England. Thereafter, on 20 February 2026, the Medicines and Healthcare products Regulatory Agency (MHRA), England wrote to King’s College London, regarding the safety and wellbeing of the participants to be recruited into the PATHWAYS clinical trial.
On 19 June 2026, the MHRA concluded its scientific dialogue with King’s College London and agreed a modified protocol as meeting the required regulatory standards.
The modified protocol was subsequently approved by the Research Ethics Committee through the Health Research Authority. The protocol includes strengthened safeguards and more information for young people and their parents or guardians, with more detailed information provided on potential risks associated with puberty-suppressing hormones. However, as legal proceedings remain ongoing, recruitment to the trial has not commenced.
Should those legal proceedings allow the PATHWAYS trial to proceed, then, as I have previously stated, I will consult Executive colleagues before reconsidering Northern Ireland's participation. The welfare and wellbeing of young people remains my priority.